A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

REPATHA® (EVOLOCUMAB) APPROVED AS FIRST PCSK9 INHIBITOR IN JAPAN FOR THE TREATMENT OF HIGH CHOLESTEROL
Jan 22, 2016
Important Milestone for Certain Japanese Patients With Uncontrolled LDL Cholesterol
First Approval for Amgen and Astellas Joint Venture